ArticleJACC. Case reports2026
Septal Embolization Using Ethylene Vinyl Alcohol Copolymer in Hypertrophic Obstructive Cardiomyopathy: 1-Year Follow-Up.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- 2026 Expert Consensus Recommendations on Hypertrophic Cardiomyopathy: A Report of the Task Force of the Taiwan Society of Cardiology.Acta Cardiologica Sinica · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypertrophic obstructive cardiomyopathy (HOCM) is a genetic cardiac disorder characterized by left ventricular outflow tract obstruction due to septal hypertrophy and mitral regurgitation. When medical therapy is insufficient, invasive strategies such as surgical myectomy or percutaneous septal ablation are considered. Alcohol septal ablation is the most common percutaneous option for patients unfit for surgery. However, concerns about the cardiotoxicity of alcohol, the risk of arrhythmias, and pacemaker have prompted exploration of safer alternatives. CASE SUMMARY: We report the case of a 71-year-old woman with symptomatic HOCM who underwent septal embolization using Onyx, a nonalcoholic embolic agent. The patient experienced significant symptomatic and hemodynamic improvement, sustained over 12 months. DISCUSSION: Although alcohol septal ablation remains the standard percutaneous option, Onyx provided targeted septal infarction under fluoroscopic guidance without alcohol-related toxicity. TAKE-HOME MESSAGE: Onyx may be a promising and safe alternative for septal reduction in selected HOCM patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.